Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

Kong, Tiandong; Chen, Lu; Zhao, Xiaoli; Duan, Fangfang; Zhou, Haofei; Wang, Lei; Liu, Danna

doi:10.1007/s10637-022-01279-7

Cited by 10 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar clinical observations were also conducted, yielding consistent findings. Another study reported an ORR of 90%, a DCR of 100%, a median PFS of 10.3 months, and a median OS of 17.1 months 24 . These results further confirm the efficacy and safety of combining anlotinib with chemotherapy.…”

Section: Discussionsupporting

confidence: 60%

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Wang,

Zhang,

Cao

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

A 67‐year‐old male patient presented with extensive‐stage small cell lung cancer with the primary lesion located in the right upper lung, accompanied by multiple metastases to the pleura and abdominal cavity with enlarged mediastinal lymph nodes. A combination therapy approach was used to target the patient's multiple systemic metastases after localized radiotherapy. The approach involved adoptive transfer of programmed death ligand 1 (PD‐L1) enhanced exogenous natural killer (NK) cells, along with antiangiogenic treatment. Allogeneic cord blood NK cells were infused back into the patient over two consecutive days. On the first day, the treatment was followed by a dose of 1200 mg of atezolizumab. Subsequently, the patient received a daily dose of 10 mg of anlotinib administered orally for 14 days. This was followed by a 7‐day break, and each cycle lasted 21 days. After delivering localized radiation to the primary lesion in the right lung and metastatic mediastinal lymph nodes, complete remission was achieved in the local lesion, effectively avoiding the risk of superior vena cava syndrome. Following six cycles of combined therapy, most of the metastatic lesions had disappeared, and the remaining metastatic lesions had significantly reduced in size. The recent therapeutic effect resulted in partial remission. The combination therapy of immune checkpoint inhibitor PD‐L1‐enhanced exogenous adoptive transfer NK cells, along with antiangiogenic targeted treatment, demonstrated a satisfactory short‐term effect, with disappearance of most of the metastases and noticeable shrinkage in the remaining metastatic lesions.

show abstract

Section: Discussionsupporting

confidence: 60%

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Wang,

Zhang,

Cao

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Researchers have found that TGF-β1 levels are higher in NSCLC patients compared to other patients. It is believed that the mechanism behind this is that cancer cells damage endothelial cells, causing TGF-β1 to leak into the bloodstream, which in turn leads to an increase in TGF-β1 levels [16,17]. In this study, the TGF-β1 levels in study group were lower than in control group after treatment, indicating that anti-PD-1 immunotherapy combined with chemotherapy can effectively repair endothelial cell damage.…”

Section: Posttreatmentmentioning

confidence: 55%

Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced nonsmall cell lung cancer

Li¹,

Fu²,

Li³

et al. 2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the clinical efficacy of anti-programmed cell death-1 (PD-1) immunotherapy in combination with chemotherapy in patients suffering from locally advanced non-small cell lung cancer (NSCLC). Methods: A total of 110 NSCLC patients admitted in The Second Affiliated Hospital of Hainan Medical University, Haikou, China were randomly divided into two groups using envelope method. The control group was administered pemetrexed and cisplatin, and the study group was further treated with nivolumab. Each treatment cycle lasted for 21 days, and a total of 6 cycles were administered for the duration of therapy. The short-term objective response rate, adverse reactions, programmed cell death5 (PDCD-5), tumor necrosis factor-α (TNF-α), tumor necrosis factor-β1 (TGF-β1), and immune status indices were determined. Results: The objective remission rate in study group was 79.25 % (42/53), which was higher than that in control group (61.40 %, 35/57; p < 0.05). After treatment, both groups showed higher levels of PDCD5 and TNF-α compared to their pre-treatment values, while demonstrating lower levels of TGF-β1. Furthermore, PDCD-5 and TNF-α in study group were higher than those in control group, while TGF-β1 was lower than that in control group (p < 0.05). In control group, the values of clusters of differentiation 3+(CD3+), 4+(CD4+), and 8+(CD8+) decreased after treatment, while the values of CD8+ increased after treatment. The CD3+, CD4+, and CD4+/CD8+ in study group were higher than those in control group, while CD8+ was lower than those in control group (p < 0.05). Conclusion: Anti-PD-1 immunotherapy combination with chemotherapy in the treatment of local NSCLC stabilizes the immune system and improves the short-term efficacy of patients with advanced NSCLC. Further clinical trials are, however, required prior to application of this combination clinical practice.

show abstract

“…Previous study had suggested that anlotinib could overcome multidrug resistance in many cancers [ 16 , 28 ]. More importantly, a recent study shows that anlotinib combined with platinum-chemotherapy has effective antitumor activity as the first-line treatment for extensive-stage small-cell lung cancer [ 29 ]. In our study, we demonstrated that anlotinib suppressed DDP resistance in NSCLC cells by regulating cell proliferation and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Wang,

Xu,

Han

et al. 2024

Canadian Respiratory Journal

View full text Add to dashboard Cite

Background. Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. Methods. Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay. The mRNA expression levels of mesenchymal-epithelial transition factor (MET) and myeloid cell leukemia-1 (MCL-1) were measured by quantitative real-time PCR. Protein expression levels of MET, MCL-1, and STAT3/Akt pathway-related markers were examined using western blot analysis. Results. Our data showed that anlotinib inhibited the DDP resistance of NSCLC cells by regulating cell proliferation and metastasis. Moreover, MET and MCL-1 expression could be decreased by anlotinib treatment. Silencing of MET suppressed the activity of the STAT3/Akt pathway and MCL-1 expression. Furthermore, MET overexpression reversed the inhibitory effect of anlotinib on the DDP resistance of NSCLC cells, and this effect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway). Conclusion. Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.

show abstract

Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

Cited by 10 publications

References 42 publications

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced nonsmall cell lung cancer

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Contact Info

Product

Resources

About